Glioma immunotherapy group
1 – 10 of 24
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Antisecretory factor in severe traumatic brain injury (AFISTBI) : protocol for an exploratory randomized placebo-controlled trial
- Contribution to journal › Article
-
Mark
Altered Neurocritical Care Management of Patients with Severe Traumatic Brain Injury Following Changed Positions of the Zero-Reference Points for Intracranial and Arterial Pressure Measurement
(2025) In Neurocritical Care
- Contribution to journal › Article
- 2024
-
Mark
Comparison of perimetric 24-2 and 30-2 test patterns in detecting visual field defects in patients with tumours in the pituitary region
- Contribution to journal › Article
-
Mark
Protumoral lipid droplet-loaded macrophages are enriched in human glioblastoma and can be therapeutically targeted
- Contribution to journal › Article
-
Mark
Treatment with BRAF/MEK : inhibitors in mutant BRAF V600E papillary craniopharyngioma
- Contribution to journal › Article
- 2023
-
Mark
Prolonged and intense neuroinflammation after severe traumatic brain injury assessed by cerebral microdialysis with 300 kDa membranes
- Contribution to journal › Article
-
Mark
Antisecretory factor is safe to use as add-on treatment in newly diagnosed glioblastoma
- Contribution to journal › Article
-
Mark
Non-functioning pituitary microadenoma in children and adolescents : Is follow-up with diagnostic imaging necessary?
- Contribution to journal › Article
-
Mark
Visual acuity in patients with non-functioning pituitary adenoma : Prognostic factors and long-term outcome after surgery
- Contribution to journal › Article
- 2022
-
Mark
Intratumoral administration of the antisecretory peptide AF16 cures murine gliomas and modulates macrophage functions
- Contribution to journal › Article
